BELLEVUE, Wash., Jan. 16, 2026 /PRNewswire/ -- Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneer in oral T-cell immunotherapies for cancer, today announced the appointment of Sébastien Wieckowski, PhD, as Chief Scientific Officer (CSO). This appointment strategically strengthens Vaximm's leadership with deep, long-standing expertise in the company's core technology. Dr. Wieckowski brings multidisciplinary experience spanning immunology and advanced data science, a profile uniquely poised to integr ...

Core Viewpoint - Cardiol Therapeutics Inc. has announced a private placement offering to raise gross proceeds of $13.5 million by selling 10,384,616 units at a price of $1.30 per unit, with an option for the underwriter to purchase an additional 10% of the units sold [1][4]. Group 1: Offering Details - The offering consists of units that include one Class A common share and one-half of a common share purchase warrant, with each warrant allowing the purchase of one common share at an exercise price of $1.75 for 24 months [2]. - The offering is scheduled to close on or about January 23, 2026, subject to necessary approvals, including TSX approval, and the negotiation of an underwriting agreement [4]. - A cash commission of 6% of the aggregate gross proceeds will be paid to the underwriter upon closing of the offering [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to advance the company's research and clinical development programs, as well as for general and administrative expenses and working capital [3]. Group 3: Company Overview - Cardiol Therapeutics is a late-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate, CardiolRx™, targeting conditions like pericarditis and myocarditis [9][10]. - The company is also developing CRD-38, a novel drug formulation for treating inflammatory heart disease, which is a significant cause of death and hospitalization in developed countries [12].

Core Viewpoint - Arch Biopartners Inc. has appointed Dr. Patrick Vink as the new Chairman of the Board of Directors, effective January 15, 2026, following the retirement of Claude Allary [1][5]. Company Leadership - Dr. Patrick Vink has extensive experience in the pharmaceutical industry, having served as an advisor since 2015 and held various board positions in public and private companies across North America and Europe [2]. - His previous roles include Executive Vice President and Chief Operating Officer of Cubist Pharmaceuticals, where he oversaw operations until its $9.5 billion acquisition by Merck in 2015 [3]. - Dr. Vink has a history with Arch Biopartners, having served as a director from December 2016 to December 2019 and as a Strategic Advisor thereafter [3]. Company Development - The appointment of Dr. Vink is seen as beneficial for Arch Biopartners as the company advances its acute kidney injury Phase II trials and chronic kidney disease program [4]. - The company is focused on developing novel drugs for acute kidney injury (AKI) and chronic kidney disease (CKD), targeting serious unmet needs affecting over 800 million people globally [7]. Board Changes - Claude Allary, who has been a director since 2014, has retired, contributing significantly to Arch's evolution into a leading kidney therapeutics company [5][6].

Core Viewpoint - Triple-leveraged ETFs, specifically the Direxion Daily S&P Biotech Bull 3X Shares (NASDAQ:LABU), are positioned as a high-risk, high-reward investment for those who believe in a significant upward movement in the biotech sector [1] Group 1: Investment Strategy - The Direxion Daily S&P Biotech Bull 3X Shares (LABU) provides an aggressive investment vehicle aimed at capitalizing on potential biotech sector growth [1]

Group 1 - Brendan, a Pennsylvanian, completed a Ph.D. at Stanford University in organic synthesis in 2009 [1] - He worked for Merck from 2009 to 2013 and has experience in biotech startups including Theravance and Aspira before joining Caltech [1] - Brendan is the first employee and co-founder of 1200 Pharma, which spun out of Caltech and secured major investments in the 8 figures [1] - He remains an avid investor focused on market trends, particularly in biotechnology stocks [1]

Core Viewpoint - Tiziana Life Sciences, Ltd. has announced a registered direct offering of 6,400,000 ordinary shares at $1.25 per share, aiming to raise approximately $8.0 million to fund clinical trials for its lead candidate, intranasal foralumab [1][3]. Group 1: Offering Details - The offering is conducted without an underwriter or placement agent and is targeted at senior management and existing shareholders [1]. - Participants in the offering will receive warrants to purchase additional shares at $1.50, potentially raising an additional $9.6 million [1]. - The offering is expected to close on January 16, 2026, pending customary closing conditions [1]. Group 2: Management Participation - CEO Ivor Elrifi purchased 2,400,000 ordinary shares, increasing his total holdings to 2,757,848 shares [2]. - Executive Chairman Gabriele Cerrone acquired 1,600,000 shares through Panetta Partners Ltd, raising his total holdings to 44,974,830 shares [2]. Group 3: Use of Proceeds - Proceeds from the offering will be utilized to complete Phase 2 clinical trials for non-active secondary progressive multiple sclerosis (na-SPMS) and multiple system atrophy (MSA), with top-line data expected from both trials [3]. Group 4: Product Information - Foralumab is a fully human anti-CD3 monoclonal antibody that stimulates T regulatory cells when administered intranasally [7]. - The drug is currently being tested in a Phase 2a trial for na-SPMS, with positive outcomes reported in an open-label program involving 14 patients [7]. - Foralumab represents a novel approach to treating neuroinflammatory and neurodegenerative diseases [8]. Group 5: Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies using alternative drug delivery technologies [8]. - The company aims to improve efficacy, safety, and tolerability of treatments compared to traditional intravenous delivery methods [8].

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced an update on the status of enrollment in its randomized registrational trial in BCG-naïve non-muscle-invasive bladder cancer (NMIBC), QUILT-2.005. Enrollment has exceeded internal expectations and is now over 85% complete, with full enrollment of the planned study population anticipated by Q2 2026. Based on the current enrollment trajectory, ImmunityBio anticipates submitting a biologics license application (. ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced updated efficacy and safety results from the ongoing QUILT-106 clinical study (NCT06334991) evaluating an off-the-shelf allogeneic CD19 chimeric antigen receptor natural killer cell therapy (CAR-NK). This CD19 t-haNK (CAR-NK) is a targeted high-affinity natural killer (NK) cell therapy engineered to express a CD19-specifc chimeric antigen receptor (CAR) used in combination with r ...

The shares have climbed on every trading day so far in 2026. The streak looks set to continue. ...

Core Viewpoint - Oncopeptides reported strong sales growth in Q4 2025, with net sales reaching SEK 18.6 million, reflecting an 88% increase year-over-year compared to Q4 2024 and a 125% increase compared to the full year of 2024 [2]. Sales Performance - The company achieved significant year-over-year growth across all key markets, particularly in Italy, which exceeded expectations [2]. - Germany, the largest market, experienced double-digit growth; however, this was not enough to offset the negative impact from Spain due to a strike among medical doctors [3]. Financial Outlook - Based on the current run rate, Oncopeptides has recalibrated its financial expectations, now anticipating cash flow positivity to occur in 2027 instead of the previously projected end of 2026 [4]. - The company remains confident in the long-term value of its European business despite the adjustments to its financial timeline [4].